Drug Trial Radar · NCT03830827
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
Last checked: Nov 19, 2026Latest source record: Nov 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
220
Planned (sponsor's estimate)
Start
Sep 1, 2020
Primary completion
Apr 30, 2021
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- Sir Run Run Shaw HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shenzhen Mental Health Center; Huazhong University of Science and Technology
- First posted
- Feb 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, double-blind, Randomized, parallel-group study in subjects with methamphetamine dependence was to assess the efficacy of MBRP combined with vortioxetine and MBRP alone on 24-week abstinence rates, improvement of cognition and depressive symptoms.
Conditions
- Relapse
- Cognitive Impairment
- Depression
Interventions
VortioxetineDrug
8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Timeline Followback (TLFB) for MA relapse ratesTime frame: 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.